SureTrader
Home > Boards > US Listed > Biotechs > NorthWest Biotherapeutics (NWBO)

Here is the link to Germany DCVax Clinical

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
john1045 Member Profile
 
Followed By 31
Posts 2,181
Boards Moderated 0
Alias Born 06/09/11
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 8/26/2016 10:37:47 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 8/26/2016 10:35:40 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 8/26/2016 10:33:23 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/23/2016 9:28:24 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/9/2016 5:13:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 7/28/2016 4:40:53 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/11/2016 5:26:56 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 7/5/2016 5:19:22 PM
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $3.7 MILLION WITH NEW INSTITUTIONAL INVESTORS "PR Newswire (US)" - 7/5/2016 9:00:00 AM
NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement "PR Newswire (US)" - 6/30/2016 5:25:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/30/2016 5:22:29 PM
Pre-Market Review on Biotechnology Equities -- Northwest Biotherapeutics, Titan Pharma, Ultragenyx Pharma, and Athersys "PR Newswire (US)" - 6/29/2016 8:30:00 AM
NW Bio Announces Scientific Advisory Board "PR Newswire (US)" - 6/13/2016 9:15:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 5/19/2016 9:26:04 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/11/2016 6:05:17 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 5/10/2016 5:49:20 PM
These Four Small Caps Are on Our Radar This Week "InvestorsHub NewsWire" - 5/4/2016 7:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/3/2016 9:05:07 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 5/3/2016 6:05:17 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/2/2016 5:25:44 PM
NW Bio Announces Operations Updates "PR Newswire (US)" - 5/2/2016 5:00:00 PM
Amended Annual Report (10-k/a) "Edgar (US Regulatory)" - 4/29/2016 6:10:06 PM
Broad Street Alerts Issues Watch List and Due Diligence Report’s "InvestorsHub NewsWire" - 4/19/2016 8:10:00 AM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 3/16/2016 3:47:34 PM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 3/15/2016 4:29:20 PM
john1045   Monday, 12/24/12 04:47:16 PM
Re: None
Post # of 71920 
Here is the link to Germany DCVax Clinical trials with an area I pasted from long report so they obviously are recruiting over there as of now....

http://translate.google.com/translate?hl=en&sl=de&u=http://www.uniklinik-duesseldorf.de/fileadmin/Datenpool/einrichtungen/universitaetstumorzentrum_id505/neu2012/Dateien/Klinische_Studien_UTZ_Duesseldorf.pdf&prev=/search%3Fq%3Ddcvax%26start%3D50%26hl%3Den%26sa%3DN%26tbo%3Dd%26biw%3D1366%26bih%3D586%26tbs%3Dqdr:w&sa=X&ei=I8nYULiqM7GH0QGx6oDACg&ved=0CGwQ7gEwCTgy

Page 11 of 23

Clinical trials in brain tumors


IND No. 10206

Glioblastoma (brain cancer)

Phase II clinical trial to evaluate DCVax-Brain, autologous dendritic cells pulsed with tumor lysate, for treatment

of glioblastoma multiforme.



A Phase II Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate for the Treatment of Glioblastoma

Multiforme

Your contact:

Prof. Dr. Michael Sabel

Michael.Sabel @ med.uni-duesseldorf.de



Page 12


Current clinical studies at University Cancer Center UTZ

University Cancer Center UTZ

Info Phone: 0211-8108200

at the University Hospital Dusseldorf

www.uniklinik-duesseldorf.de/utz

Stand: 01/2013

Page 12 of 23

Clinical trials in brain tumors

Fraunhofer Institute

Glioblastoma (brain cancer)

Phase II clinical study evaluating DCVax ®-L Brain autologous dendritic cells loaded with tumor lysate antigen for

Treatment of glioblastoma multiforme (GBM)

Clinical phase II trial to evaluate DCVax ®-L Brain autologous dendritic cells loaded with tumor lysate antigen for treatment of glioblastoma

multiforme (GBM)

Your contact:

Infoline

Tel: 0211-8108200

uta@med.uni-duesseldorf.de


SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist